A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

@article{Ho2017ASO,
  title={A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.},
  author={Thai H. Ho and Rafael Alejandro N{\'u}{\~n}ez-Nateras and Yue-xian Hou and Alan H Bryce and Donald W. Northfelt and Amylou C. Dueck and Bryan Y. Wong and Melissa L. Stanton and Richard W. Joseph and Erik Peter Castle},
  journal={Clinical genitourinary cancer},
  year={2017},
  volume={15 2},
  pages={
          196-202.e1
        }
}
BACKGROUND Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β, and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a selective ER modulator, has inhibited the growth of prostate cancer xenograft models and was tested in a phase II trial of castration-resistant prostate cancer (CRPC), with some patients achieving stable disease. However, no studies have examined the safety of the combination of bicalutamide plus raloxifene for CRPC… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Diethylstilbestrol in castration-resistant prostate cancer.

Anna C Wilkins, Mehdi Shahidi, +5 authors David Dearnaley
  • BJU international
  • 2012
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…